Testing effectiveness (Phase 2)Study completedNCT03561870What this trial is testingOlaparib in Recurrent IDH-mutant GliomaWho this might be right forRecurrent IDHMutant High Grade Glioma Hospices Civils de Lyon 35
Large-scale testing (Phase 3)Active Not RecruitingNCT06780930What this trial is testingPhase 3 Study of Vorasidenib (S095032/AG-881) in Asian Participants With Residual or Recurrent Grade 2 Glioma With an IDH1 orIDH2 MutationWho this might be right forResidual or Recurrent Grade 2 IDH Mutant Glioma Servier 57
Testing effectiveness (Phase 2)Looking for participantsNCT07416188What this trial is testingNovel Indenoisoquinolone CMYC/TOPOISOMERASE 1 Inhibitor (LMP744) in Recurrent GlioblastomaWho this might be right forRecurrent GlioblastomaGlioblastoma IDH (Isocitrate Dehydrogenase) WildtypeRelapsed Cancer+12 more National Institute of Neurological Disorders and Stroke (NINDS) 40
Testing effectiveness (Phase 2)Study completedNCT04740190What this trial is testingTalazoparib - Carboplatin for Recurrent High-grade Glioma With DDRdWho this might be right forRecurrent GliomaRecurrent GlioblastomaPoly ADP Ribose Polymerase (PARP) Inhibitor+2 more The University of Hong Kong 33
Early research (Phase 1)Study completedNCT04908176What this trial is testingA Drug-drug Interaction Study of Avapritinib and MidazolamWho this might be right forGastrointestinal Stromal TumorsGISTNon-resectable Advanced Solid Tumors+1 more Blueprint Medicines Corporation 10
Testing effectiveness (Phase 2)Looking for participantsNCT07318818What this trial is testingA Clinical Trial of P134 Cells in Recurrent GlioblastomaWho this might be right forRecurrent Glioblastoma IDH Wildtype Tasly Pharmaceutical Group Co., Ltd 26
Early research (Phase 1)Not Yet RecruitingNCT07385846What this trial is testingPilot Study of Navigated Focused Ultrasound and Pembrolizumab in the Treatment of Recurrent WHO Grade 4 IDH-Wildtype Glioblastoma With Mismatch Repair DeficiencyWho this might be right forGlioblastomaMismatch Repair Deficiency Jennifer Leddon 8
Testing effectiveness (Phase 2)WithdrawnNCT05218408What this trial is testingCYNK-001 IV and IC in Combination With IL2 in Surgical Eligible Recurrent GBM With IDH-1 Wild TypeWho this might be right forAstrocytoma, Grade IVGlioblastomaGiant Cell Glioblastoma+1 more Celularity Incorporated
Not applicableLooking for participantsNCT06430424What this trial is testingStudy of Metabolic, Transcriptomic and Proteomic Characteristics in Relapsed GlioblastomaWho this might be right forRelapsed CancerGlioblastoma IDH (Isocitrate Dehydrogenase) Wildtype University Hospital, Bordeaux 40
Very early researchActive Not RecruitingNCT06824662What this trial is testingPhase 0 With Expansion Phase Clinical Trial of Quisinostat Plus Radiotherapy in Newly-diagnosed and Recurrent Grade 4 IDH-Wildtype GlioblastomasWho this might be right forGlioblastoma WHO Grade IV Nader Sanai 30
Not applicableUnknownNCT04908267What this trial is testingHow the Precise Habitats Can Predict the IDH Mutation Status and Prognosis of the Patients With High-grade GliomasWho this might be right forHigh-grade Glioma Weiguo Zhang 100
Testing effectiveness (Phase 2)Active Not RecruitingNCT03953898What this trial is testingUsing the Anticancer Drug Olaparib to Treat Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome With an Isocitrate Dehydrogenase (IDH) MutationWho this might be right forAcute Myeloid LeukemiaAcute Myeloid Leukemia Arising From Previous Myelodysplastic SyndromeAcute Myeloid Leukemia Post Cytotoxic Therapy+4 more National Cancer Institute (NCI) 14
Testing effectiveness (Phase 2)Active Not RecruitingNCT04729959What this trial is testingTesting the Addition of the Immune Therapy Drugs, Tocilizumab and Atezolizumab, to Radiation Therapy for Recurrent GlioblastomaWho this might be right forDiffuse Astrocytoma, IDH-WildtypeRecurrent Glioblastoma National Cancer Institute (NCI) 61
Early research (Phase 1)Not Yet RecruitingNCT07629089What this trial is testingVorAsidenib With Lomustine In Patients With rEcurrent IDH-mutaNT Glioma Harboring IDH1 and/or IDH2 MutationsWho this might be right forBrain Cancer Megan Mantica 24
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07120984What this trial is testingEvaluate the Safety and Efficacy of L19TNF With Alkylating Chemotherapy for Patients With Recurrent IDH-mutant Astrocytoma or OligodendrogliomaWho this might be right forGlioma Philogen S.p.A. 52
Early research (Phase 1)Enrolling By InvitationNCT06896110What this trial is testingIntrathecal Azacitidine and Nivolumab in Patients With Recurrent High-grade GliomaWho this might be right forGlioblastoma (GBM)Diffuse Midline Glioma (DMG)Astrocytoma, IDH-Mutant, Grade 4+2 more Andrew P. Groves 34
Testing effectiveness (Phase 2)Looking for participantsNCT06776250What this trial is testingStudy of How Safe and Effective Tarlatamab is in Brain CancersWho this might be right forAstrocytic TumorOligodendroglial Tumor University Health Network, Toronto 44
Early research (Phase 1)Not Yet RecruitingNCT07422363What this trial is testingTesting the Combination of Anti-cancer Drugs Actimab-A and Cemiplimab (REGN2810) to Improve Outcomes for Patients With Recurrent GlioblastomaWho this might be right forRecurrent Glioblastoma, IDH-WildtypeRecurrent GliosarcomaRecurrent WHO Grade 4 Glioma National Cancer Institute (NCI) 30
Early research (Phase 1)Looking for participantsNCT03922555What this trial is testingASTX727 in Recurrent/Progressive Non-enhancing IDH Mutant GliomasWho this might be right forNeurological Cancer Massachusetts General Hospital 18
Testing effectiveness (Phase 2)Study completedNCT03925246What this trial is testingEfficacy of Nivolumab for Recurrent IDH Mutated High-Grade GliomasWho this might be right forHigh Grade GliomaBrain Cancer Assistance Publique - Hôpitaux de Paris 43